Keyphrases
Left Ventricular Mass
68%
Hemodialysis Patients
62%
Cardiac Magnetic Resonance Imaging (cMRI)
55%
T1 Mapping
50%
Hemodialysis
50%
Randomized Controlled Trial
50%
Allopurinol
50%
End-stage Renal Failure
50%
Myocardial Tissue
50%
Global Longitudinal Strain
18%
T1 Time
18%
Myocardial Fibrosis
18%
Regress
16%
Healthy Volunteers
12%
End-stage Renal Disease
11%
Placebo
11%
Pulse Wave Velocity
11%
Flow-mediated Dilation
11%
Native T1 Time
6%
Nephrogenic Systemic Fibrosis
6%
T1 Relaxation Time
6%
Cardiac Biomarkers
6%
Fibrosis Marker
6%
Non-invasive Quantification
6%
Incident Hemodialysis Patients
6%
Gadolinium-based Contrast Agents
6%
Time Tracking
6%
Structural Abnormalities
6%
Corrected QT Interval
6%
Functional Abnormalities
6%
Tissue Properties
6%
Feature Tracking
6%
Surrogate Marker
6%
Magnetic Resonance Imaging
6%
Galectin-3 (Gal-3)
6%
Cardiac Fibrosis
6%
Troponin
6%
Dialysis Session
5%
Index Regression
5%
Index Changes
5%
Routine Maintenance
5%
Improved Outcomes
5%
Glasgow
5%
Ayrshire
5%
Ischemic Heart Disease
5%
Tayside
5%
British Heart Foundation
5%
Chronic Kidney Disease
5%
Randomized Placebo-controlled Trial
5%
Placebo Treatment
5%
Maintenance Hemodialysis
5%
Diabetes
5%
Imaging Follow-up
5%
Augmentation Index
5%
Cardiac Magnetic Resonance
5%
Multicenter Trial
5%
Scotland
5%
Immunology and Microbiology
Hemodialysis
100%
Heart Left Ventricle Mass
63%
Magnetic Resonance Imaging
61%
Allopurinol
50%
Pulse Wave
11%
Normal Human
9%
Medicine and Dentistry
Randomized Controlled Trial
50%
Hemodialysis
50%
Allopurinol
50%
Placebo
25%
Cardiac Magnetic Resonance Imaging
12%
Pulse Wave Velocity
12%
Ischemic Heart Disease
6%
End Stage Renal Disease
6%
Diabetes
6%
Chronic Kidney Disease
6%